Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07111520) titled 'A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)' on Aug. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: BioNTech SE
Condition:
Non-small Cell Lung Cancer
Intervention:
Drug: BNT326
Drug: BNT327
Drug: Pembrolizumab
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: September 2025
Target Sample Size: 420 ...